Browse the complete record of transactions filed by Florent Pons, Membre du comité de direction de genOway. Insider active across 1 companies, notably GENOWAY. Cumulatively, 5 filings have been recorded. Total volume traded: €28k. The latest transaction was disclosed on 11 April 2025 — Acquisition. Regulator: AMF. All data is openly available.
5 of 5 declarations
Florent Pons holds a leadership position at genOway, a Lyon-based biotechnology company focused on preclinical models and research solutions for pharmaceutical companies and academic institutions. genOway’s corporate website lists him among the members of the company’s current management committee, placing him within the core executive group that helps steer the firm’s strategy, operations and growth. The company specializes in genetically engineered mice, rats and cell lines, with a strong emphasis on immuno-oncology, immunotherapy and highly predictive translational models. Publicly available information suggests that Florent Pons is closely associated with the commercial and marketing side of the business. External professional sources have described him as Director of Commercial Operations and as Chief Marketing Officer, indicating responsibilities tied to revenue development, offer positioning and customer engagement. In a biotechnology environment, this type of role typically requires turning complex scientific capabilities into compelling commercial value propositions for pharma, biotech and academic clients, while supporting international market expansion. At genOway, the commercial challenge is highly strategic. The company operates in a demanding field where scientific credibility, model customization and predictive performance are key differentiators. Florent Pons’s place in the management committee therefore suggests that he contributes to aligning go-to-market priorities, brand positioning and business development with the company’s broader growth agenda. His profile fits a governance model that combines scientific excellence with commercial execution, international visibility and long-term value creation. More broadly, his role appears to support genOway’s transition from a niche scientific specialist to a more scalable and market-facing biotech platform. By helping structure the company’s commercial approach and strengthen its positioning with external stakeholders, Florent Pons seems to play an important part in converting technological expertise into sustainable business momentum.